(Q35046503)

6 August 2017

1 reference

title

Aldosterone: a risk factor for vascular disease (English)

1 reference

6 August 2017

0 references

Mario Fritsch Neves

1

1 reference

6 August 2017

Ernesto L Schiffrin

series ordinal

2

1 reference

6 August 2017

publication date

1 February 2003

1 reference

Current Hypertension Reports

6 August 2017

published in

1 reference

6 August 2017

volume

5

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

59-65

1 reference

Cellular hypertrophy in subcutaneous small arteries of patients with renovascular hypertension.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

The transcription factor NF-kappa B and the regulation of vascular cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

Myocardial fibrosis in DOCA-salt hypertensive rats: effect of endothelin ET(A) receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

Limitation of Excessive Extracellular Matrix Turnover May Contribute to Survival Benefit of Spironolactone Therapy in Patients With Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-003-0012-2

Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy.

21 January 2018

1 reference

12 December 2020

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

12 December 2020

Synergistic effect of adrenal steroids and angiotensin II on plasminogen activator inhibitor-1 production

1 reference

12 December 2020

Impaired baroreflex function and arterial compliance in primary aldosteronism.

1 reference

12 December 2020

Interactions between endothelin-1 and the renin-angiotensin-aldosterone system

1 reference

12 December 2020

Cautions over the current epidemic of primary aldosteronism

1 reference

12 December 2020

Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology

1 reference

12 December 2020

Primary aldosteronism: revival of a syndrome

1 reference

12 December 2020

Interaction of rapid nongenomic cardiovascular aldosterone effects with the adrenergic system

1 reference

12 December 2020

Human arterial hypertension: a state of mild chronic hyperaldosteronism?

1 reference

12 December 2020

A review of the medical treatment of primary aldosteronism

1 reference

12 December 2020

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

1 reference

12 December 2020

Spironolactone abolishes the relationship between aldosterone and plasminogen activator inhibitor-1 in humans

1 reference

12 December 2020

Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries

1 reference

12 December 2020

Mineralocorticoid receptor antagonism in experimental atherosclerosis

1 reference

12 December 2020

Left ventricular hypertrophy and remodelling of resistance arteries: the role of activation of the renin-angiotensin-aldosterone system in hypertension.

1 reference

12 December 2020

Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats

1 reference

12 December 2020

Plasminogen-activator inhibitor type 1 and coronary artery disease

1 reference

12 December 2020

Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism

1 reference

12 December 2020

Aldosterone as a determinant of cardiovascular and renal dysfunction

1 reference

12 December 2020

Primary aldosteronism: rare bird or common cause of secondary hypertension?

1 reference

12 December 2020

Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor

1 reference

12 December 2020

NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats

1 reference

12 December 2020

Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1.

1 reference

12 December 2020

Inhibition of mineralocorticoid-mediated transcription by NF-kappaB.

1 reference

12 December 2020

Pathophysiological effects of aldosterone in cardiovascular tissues

1 reference

12 December 2020

Spironolactone improves angiotensin-induced vascular changes and oxidative stress

1 reference

12 December 2020

The endothelin-aldosterone axis and cardiovascular diseases.

1 reference

12 December 2020

Cardiovascular complications in patients with primary aldosteronism

1 reference

12 December 2020

Aldosterone augments endothelin-1-induced cardiac myocyte hypertrophy with the reinforcement of the JNK pathway

1 reference

12 December 2020

The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism?

1 reference

12 December 2020

Structural changes in small resistance arteries and left ventricular geometry in patients with primary and secondary hypertension

1 reference

12 December 2020

Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure

1 reference

12 December 2020

Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Aldosterone: a mediator of myocardial necrosis and renal arteriopathy

1 reference

12 December 2020

Effects of long-term enalapril and losartan therapy of hypertension on cardiovascular aldosterone

1 reference

12 December 2020

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study

1 reference

12 December 2020

Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients

1 reference

12 December 2020

Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors

1 reference

12 December 2020

Small artery remodeling is the most prevalent (earliest?) form of target organ damage in mild essential hypertension

1 reference

12 December 2020

Altered aldosterone response to salt intake and angiotensin II infusion in young normotensive men with parental history of arterial hypertension

1 reference

12 December 2020

Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts

1 reference

12 December 2020

Induction of cardiac fibrosis by aldosterone

1 reference

12 December 2020

Mineralocorticoid and angiotensin receptor antagonism during hyperaldosteronemia

1 reference

12 December 2020

High serum level of procollagen type III amino-terminal peptide contributes to the efficacy of spironolactone and angiotensin-converting enzyme inhibitor therapy on left ventricular hypertrophy in essential hypertensive patients

1 reference

12 December 2020

Hyperaldosteronemia in rabbits inhibits the cardiac sarcolemmal Na(+)-K(+) pump

1 reference

12 December 2020

10.1007/S11906-003-0012-2

Identifiers

DOI

1 reference

6 August 2017

1 reference